Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women.

PURPOSE The purpose of this research was to examine the DNA methylation profiles of primary sporadic ovarian cancers and ovarian tissues from high-risk women. EXPERIMENTAL DESIGN We analyzed the DNA methylation status of nine cancer-related genes in 49 primary ovarian tumors, 39 nonmalignant ovarian tissues obtained from 16 women with no known risk and from 23 high-risk women with a strong family history of breast and/or ovarian cancer or BRCA1 germ-line mutations, and 11 ovarian cancer cell lines, by methylation-specific PCR. RESULTS Our findings are as follows: (a) methylation rates of four of nine genes, RASSF1A (41%), HIC1 (35%), E-cadherin (29%), and APC (18%) were significantly higher in tumors compared with controls. At least one of the four genes was methylated in 76% of the tumors; (b) a low frequency of methylation was present in nonmalignant tissues; (c) no significant differences in methylation frequencies were seen between the nonmalignant ovarian tissues from women at high-risk and those with no known risk of developing ovarian cancer; (d) methylation of the BRCA1 gene was found in 10% of sporadic tumors but in none of the samples from women with a germ-line BRCA1 mutation; and (e) ovarian cancer cell lines showed a similar frequency of methylation to ovarian tumors except for the HIC1 gene. CONCLUSIONS Our results suggest that aberrant methylation of specific genes, including two not described previously, may be important in ovarian cancer pathogenesis but not in ovaries at risk for cancer development.

[1]  Y. Nakamura,et al.  Allelotype of human ovarian cancer. , 1991, Cancer research.

[2]  J. Herman,et al.  Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. , 2000, Cancer research.

[3]  J. Issa,et al.  CpG-island methylation in aging and cancer. , 2000, Current topics in microbiology and immunology.

[4]  J. Shepherd,et al.  FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. , 1999, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[5]  D G Altman,et al.  A prognostic model for ovarian cancer , 2001, British Journal of Cancer.

[6]  M. Morgan,et al.  Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. , 1996, The New England journal of medicine.

[7]  M. Toyota,et al.  Detection of hypermethylation of thep16INK4A gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus , 2001, Gut.

[8]  R. Hruban,et al.  Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived , 2002, Oncogene.

[9]  D. F. Easton,et al.  The genetics of breast and ovarian cancer. , 1995, British Journal of Cancer.

[10]  A. Godwin,et al.  Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. , 1996, Journal of the National Cancer Institute.

[11]  J. Scoazec,et al.  Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. , 1997, Human pathology.

[12]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[13]  R. L. Baldwin,et al.  BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. , 2000, Cancer research.

[14]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[15]  A. Sakurada,et al.  The H-cadherin (CDH13) gene is inactivated in human lung cancer , 1998, Human Genetics.

[16]  J Herman,et al.  Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  J. Felix,et al.  Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. , 1999, Gynecologic oncology.

[18]  G. Chenevix-Trench,et al.  Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours , 1997, International journal of cancer.

[19]  A. Gazdar,et al.  Aberrant methylation during cervical carcinogenesis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  L. Hartmann,et al.  Human epithelial ovarian cancer allelotype. , 1993, Cancer research.

[21]  J. Minna,et al.  Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. , 2001, Cancer research.

[22]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[23]  T. Bestor,et al.  Cytosine methylation and human cancer. , 2000, Current opinion in oncology.

[24]  Issa Jp.  CpG-island methylation in aging and cancer. , 2000 .

[25]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[26]  M. Caligiuri,et al.  Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.

[27]  J. Herman,et al.  Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. , 1998, Cancer research.

[28]  J. Minna,et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.

[29]  J. Minna,et al.  ACCELERATED DISCOVERY Promoter Methylation and Silencing of the Retinoic Acid Receptor- Gene in Lung Carcinomas , 2000 .

[30]  L. Hartmann,et al.  Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. , 1999, International journal of oncology.

[31]  J. Shepherd,et al.  FIGO staging of gynecologic cancer , 1999 .

[32]  J. Herman,et al.  Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  X. Matías-Guiu,et al.  Loss of heterozygosity on chromosome 13q12–q14, BRCA‐2 mutations and lack of BRCA‐2 promoter hypermethylation in sporadic epithelial ovarian tumors , 2001, Cancer.

[35]  J. Herman,et al.  Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.

[36]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[37]  W. Thompson,et al.  The genetic attributable risk of breast and ovarian cancer , 1996, Cancer.

[38]  K. Nephew,et al.  DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. , 2001, Gynecologic oncology.

[39]  Robert C. Bast,et al.  Ovarian cancer: screening, treatment, and followup. , 1995, NIH consensus statement.

[40]  G. Yang,et al.  Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. , 2001, Cancer research.

[41]  J. Felix,et al.  Differences inp16Gene Methylation and Expression in Benign and Malignant Ovarian Tumors , 1999 .

[42]  S. Weitzman,et al.  Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer , 1998, Oncogene.

[43]  T. Tong,et al.  Cancer statistics, 1994 , 1994, CA: a cancer journal for clinicians.

[44]  J. Boyd,et al.  Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. , 2000, JAMA.

[45]  J. Herman,et al.  Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours , 2002, The Journal of pathology.

[46]  H. S. Kim,et al.  Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  K. Offit,et al.  Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes , 2000, Cancer.

[48]  J. Minna,et al.  Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. , 2001, Journal of the National Cancer Institute.

[49]  H. Lynch,et al.  Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. , 2000, Gynecologic oncology.

[50]  J. Herman,et al.  Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. , 1998, Cancer research.

[51]  R. Scully.  Pathology of ovarian cancer precursors , 1995, Journal of cellular biochemistry. Supplement.

[52]  G. Pfeifer,et al.  Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas , 2001, International journal of cancer.

[53]  G. Chenevix-Trench,et al.  Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. , 2000, Carcinogenesis.

[54]  Chun-Fang Xu,et al.  Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics , 1999, Oncogene.

[55]  G. Strathdee,et al.  A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer , 1999, Oncogene.

[56]  Robert Brown,et al.  Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. , 2001, The American journal of pathology.

[57]  J. Herman,et al.  DNA hypermethylation in tumorigenesis: epigenetics joins genetics. , 2000, Trends in genetics : TIG.